Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business
Sakshi Kumari

Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

Laurus Labs has been transforming its business mix, reducing its dependence on anti-retroviral (ARV) drugs and expanding its contract development and manufacturing organisation (CDMO) business. Nuvama believes this shift could drive the drugmaker’s next phase of growth.

Also Read: PC Jeweller, Shanti Gold & other jewellery stocks rally up to 10%. Here’s why

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.